Claims

1. Use of *N,N-bis*-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of paracetamol toxicity.

2. Use of *N,N-bis*-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of acute liver failure associated with paracetamol toxicity.

3. A pharmaceutical formulation comprising:

(a) *N,N-bis*-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically-acceptable salt thereof; and

(b) paracetamol,

and optionally one or more pharmaceutically-acceptable excipients.

4. ~~A kit-of-parts comprising components:~~

~~(A)~~ Use of a pharmaceutical formulation (A) comprising *N,N-bis*-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceutically-acceptable salt thereof, and optionally one or more pharmaceutically-acceptable excipients; and

~~(B)~~ a pharmaceutical formulation (B) comprising paracetamol, and optionally one or more pharmaceutically-acceptable excipients; ~~,~~

for the manufacture of a medicament for prevention of paracetamol toxicity and/or prevention of acute liver failure associated with paracetamol toxicity, wherein ~~which components~~ pharmaceutical formulations (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other ~~for prevention of paracetamol toxicity and/or prevention of acute liver failure associated with paracetamol toxicity~~.